The enactment of subordinate statutes for the so-called ‘preferential drug pricing for Korean Innovative Pharmaceutical Companies’ clause of the ‘Special Act On Fostering and Support of Pharmaceutical Industry’ is hardly picking up speed.

Although the research service ordered by the Ministry of Health and Welfare and the Korea Health Industry Development Institute and conducted by Professor Mi-Hye Park’s research team at the School of Pharmacy at Sungkyunkwan University, has been completed, the authorities are known to be having difficulty in preparing the specific provisions for the statute.

On the 5th, the MOHW responded that it is “supplementing the final result reports, includ